The Cash Component Of The Aggregate Merger Consideration Will Be A Base Cash Amount Of $9,005,000 (Consisting Of A Value Of $15M Minus The $5,995,000 Advanced To Kineta Under The Exclusivity And Right Of First Offer Agreement)

Benzinga12/12 22:49

TuHURA Biosciences To Acquire Kineta, Cash Component Of Merger Consideration Will Be Base Cash Amount Of $9,005,000 Less The Sum Of Kineta's Working Capital Deficit At Closing; In Connection With Merger, TuHURA And Kineta Entered Clinical Trial...

Benzinga12/12 21:51

プロテオスタシス・セラピューティクス | 10-Q：四半期報告書

SEC11/07 05:09

News On Kineta Inc. (KA) Now Under KANT

Dow Jones09/21 05:08

Kineta Shares Are Trading Higher After the Company Announced It Reopened Patient Enrollment for Its VISTA-101 Clinical Trial.

Benzinga08/19 21:06

キネタ | 10-Q：Q2 2024 四半期報告書

SEC08/09 04:14